TABLE 2.
Clinical response by key causative pathogen in microbiologic ITT populationa
| Pathogen by response timeb | 200 mg tedizolid once daily (n = 406) |
600 mg linezolid twice daily (n = 412) |
||
|---|---|---|---|---|
| No./total no.c | % | No./total no.c | % | |
| Early clinical response | ||||
| Staphylococcus aureus | 280/329 | 85.1 | 276/342 | 80.7 |
| MRSA | 114/141 | 80.9 | 111/146 | 76.0 |
| USA300 strain | 100/127 | 78.7 | 83/110 | 75.5 |
| MSSA | 166/188 | 88.3 | 167/198 | 84.3 |
| PVL-positive S. aureus | 157/190 | 82.6 | 139/181 | 76.8 |
| Streptococcus pyogenes | 25/33 | 75.8 | 16/20 | 80.0 |
| Streptococcus anginosus group | 22/30 | 73.3 | 25/28 | 89.3 |
| Clinical response at PTE | ||||
| S. aureus | 331/374 | 88.5 | 303/342 | 88.6 |
| MRSA | 151/178 | 84.8 | 119/146 | 81.5 |
| USA300 strain | 105/127 | 82.7 | 92/110 | 83.6 |
| MSSA | 180/196 | 91.8 | 186/198 | 93.9 |
| PVL-positive S. aureus | 164/190 | 86.3 | 153/181 | 84.5 |
| S. pyogenes | 30/33 | 90.9 | 19/20 | 95.0 |
| S. anginosus group | 21/30 | 70.0 | 25/28 | 89.3 |
a
ITT, intent-to-treat.
b
MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; PVL, Panton-Valentine leukocidin; PTE, posttherapy evaluation.
c
No. of patients with clinical response/total no. of patients with the particular causative pathogen.